Developing Dynamic Substrate Targeted Personalised Treatment Strategies in AF.

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Atrial fibrillation (AF) is the most common arrhythmia with an expected rise in prevalence over the next decade. Catheter ablation is a safe treatment option in eliminating AF however, success rates still remains variable. Existing strategies do not take into account the differences in AF perpetuation mechanisms beyond the pulmonary veins (PVs) due to the underlying substrate. Here, I will investigate the differences in persistent AF mechanisms due to the underlying substrate and utilise these findings to generate AF mechanism specific ablation strategies. I have defined a new metric, rate-dependent conduction velocity (RDCV) slowing that has shown to correlate with sites of re-entry activity in AF. In this study, techniques and methods will be developed to measure RDCV slowing sites. The impact autonomic modulation has on AF mechanisms and CV dynamics will also be assessed. The hypothesis is that a combination of structural, electrical and autonomic remodelling play an important mechanistic role in persistent AF and ablation strategies adapted to target these will result in greater procedural success rate. The study findings have the potential to improve the success rate of catheter ablation in persistent AF thereby improve patient wellbeing and reduce the cost burden of AF treatment.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patients undergoing catheter ablation for persistent AF (\<24 months AF duration and no previous left atrial ablation).

• Able to provide informed consent

Locations
Other Locations
United Kingdom
Barts Heart Centre, Barts Health NHS trust
RECRUITING
London
Contact Information
Primary
Shohreh Honarbakhsh, MRCP, BSc, PhD
shohreh.honarbakhsh@nhs.net
020 3765 8682
Time Frame
Start Date: 2022-10-14
Estimated Completion Date: 2027-10-10
Participants
Target number of participants: 160
Treatments
Experimental: Patients with underlying LVZs (≥30% of LVZs in the LA body)
Study 1- Developing a methodology and technique for sequential CV assessment. Twenty patients.~Study 2- Assess the mechanistic importance of RDCV slowing sites in AF. Twenty patients.~Study 3- Assess the impact autonomic modulation has on CV dynamics and RDCV slowing sites. Twenty patients.~Study 4- GP site ablation and substrate modification guided by RDCV slowing sites whereby substrate ablation is limited to substrate with these electrical properties and the impact on freedom from AF/AT during 12 months follow-up. Forty patients.~. Study 5- RDCV slowing sites and GP site identification on cardiac MRI. Twenty patients.
Experimental: Patients without underlying LVZs (<30% of LVZs in the LA body)
Study 1- Mechanistic importance of GP site ablation. Twenty patients.~Study 2- GP site ablation in addition to PV isolation and the impact on freedom from AF/AT during 12 months follow-up. Forty patients.~Study 3- RDCV slowing sites and GP site identification on cardiac MRI. Twenty patients.
Related Therapeutic Areas
Sponsors
Leads: Barts & The London NHS Trust

This content was sourced from clinicaltrials.gov